A phase IB dose-escalation trial of isatuximab (SAR650984, anti-CD38 MAB) plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM): Interim results from 2 new dose cohorts Meeting Abstract

   


Authors: Lendvai, N.; Vij, R.; Martin, T. G.; Baz, R.; Campana, F.; Mazuir, F.; Charpentier, E.; Benson, D. M.
Abstract Title: A phase IB dose-escalation trial of isatuximab (SAR650984, anti-CD38 MAB) plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM): Interim results from 2 new dose cohorts
Meeting Title: 21st Congress of the European Hematology Association (EHA)
Journal Title: Haematologica
Volume: 101
Issue: Suppl. 1
Meeting Dates: 2016 Jun 9-12
Meeting Location: Copenhagen, Denmark
ISSN: 0390-6078
Publisher: Ferrata Storti Foundation  
Date Published: 2016-06-01
Start Page: 84
Language: English
ACCESSION: WOS:000379484600181
PROVIDER: wos
PMCID: PMC4894295
Notes: Meeting Abstract: P278 -- Source: Wos